Your browser doesn't support javascript.
loading
Development of a Sol Particle Homogeneous Immunoassay for Measuring Full-Length Selenoprotein P in Human Serum.
Tanaka, Mutsumi; Saito, Yoshiro; Misu, Hirofumi; Kato, Seiji; Kita, Yuki; Takeshita, Yumie; Kanamori, Takehiro; Nagano, Toru; Nakagen, Masatoshi; Urabe, Takeshi; Takamura, Toshinari; Kaneko, Shuichi; Takahashi, Kazuhiko; Matsuyama, Naoto.
Afiliação
  • Tanaka M; Diagnostic R&D, Development & Production Headquarters, Alfresa Pharma Corporation, Ibaraki City, Osaka, Japan.
  • Saito Y; Department of Medical Life Systems, Faculty of Life and Medical Sciences, Doshisha University, Kyotanabe, Kyoto, Japan.
  • Misu H; Department of Disease Control and Homeostasis, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Ishikawa, Japan.
  • Kato S; Diagnostic R&D, Development & Production Headquarters, Alfresa Pharma Corporation, Ibaraki City, Osaka, Japan.
  • Kita Y; Department of Disease Control and Homeostasis, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Ishikawa, Japan.
  • Takeshita Y; Department of Disease Control and Homeostasis, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Ishikawa, Japan.
  • Kanamori T; Department of Disease Control and Homeostasis, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Ishikawa, Japan.
  • Nagano T; Public Central Hospital of Matto Ishikawa, Hakusan, Ishikawa, Japan.
  • Nakagen M; Public Central Hospital of Matto Ishikawa, Hakusan, Ishikawa, Japan.
  • Urabe T; Public Central Hospital of Matto Ishikawa, Hakusan, Ishikawa, Japan.
  • Takamura T; Department of Disease Control and Homeostasis, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Ishikawa, Japan.
  • Kaneko S; Department of Disease Control and Homeostasis, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Ishikawa, Japan.
  • Takahashi K; Department of Nutritional Biochemistry, Hokkaido Pharmaceutical University, Otaru, Hokkaido, Japan.
  • Matsuyama N; Diagnostic R&D, Development & Production Headquarters, Alfresa Pharma Corporation, Ibaraki City, Osaka, Japan.
J Clin Lab Anal ; 30(2): 114-22, 2016 Mar.
Article em En | MEDLINE | ID: mdl-25545464
BACKGROUND: Selenoprotein P (SeP), a selenium-rich extracellular glycoprotein, is the primary selenoprotein in the plasma. SeP plays an important role in the maintenance of selenium levels in the peripheral tissues. We developed a new sol particle homogeneous immunoassay (SPIA) for measuring full-length SeP (FL-SeP) levels in the human serum. METHODS: We used colloidal gold particles coated with two types of anti-SeP monoclonal antibodies, one recognizing the N-terminal side domain of SeP and the other recognizing the C-terminal side domain. RESULTS: The assay range was 0.2-9 mg/l, and the linearity was excellent. The within-day and between-day coefficients of variation ranged from 0.73% to 2.24% and 0.45% to 1.11%, respectively. Serum samples (n = 200) were examined using the newly developed assay system (employing a Model 7070 Hitachi automatic clinical analyzer) and the conventional enzyme-linked immunosorbent assay. These two methods were compared using the Passing-Bablok regression analysis; the resulting regression equation and correlation coefficient were y = 0.940x + 0.165 and r = 0.954, respectively. CONCLUSIONS: Our new SPIA assay is a fully automated homogeneous immunoassay that can be used in conjunction with various commercial analyzers. The assay was sensitive, precise, and suitable for clinical measurement of the FL-SeP in the human serum.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Imunoensaio / Selenoproteína P Limite: Humans Idioma: En Ano de publicação: 2016 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Imunoensaio / Selenoproteína P Limite: Humans Idioma: En Ano de publicação: 2016 Tipo de documento: Article